Peroxisome-proliferator-activated receptors γ and peroxisome-proliferator-activated receptors β/δ and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain

Journal of Hypertension

Volumn 28, Issue 7, 2010, Pages 1488-1497

  Glatz, Torben ^a   Stöck, Ivonne ^a   Nguyen Ngoc, Miriam ^a   Gohlke, Peter ^a   Herdegen, Thomas ^a   Culman, Juraj ^a   Zhao, Yi ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

cerebral ischaemia; interleukin 1 receptor antagonist; interleukin 1b; neuroprotection; pioglitazone; PPAR; rat

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN ISCHEMIA; CELL COUNT; CELL SURVIVAL; EXCITOTOXICITY; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; WESTERN BLOTTING;

EID: 77954383974     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283396e4e     Document Type: Article

References (34)

1. DirnaglU, Iadecola C,Moskowitz MA. Pathobiology of ischaemicstroke: an integrated view. Trends Neurosci 1999; 22:391-397.
2. Touzani O, Boutin H, Chuquet J, Rothwell N. Potential mechanisms of interleukin-1 involvement in cerebral ischaemia. J Neuroimmunol 1999; 100:203-215.
3. Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci 2000; 23:618-625.
4. Hill JK, Gunion-Rinker L, Kulhanek D, Lessov N, Kim S, Clark WM, et al. Temporal modulation of cytokine expression following focal cerebral ischemia in mice. Brain Res 1999; 820:45-54.
5. Legos JJ, Whitmore RG, Erhardt JA, Parsons AA, Tuma RF, Barone FC. Quantitative changes in interleukin proteins following focal stroke in the rat. Neurosci Lett 2000; 282:189-192.
6. Rothwell N. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immun 2003; 17:152-157.
7. Hara H, Friedlander RM, Gagliardini V, Ayata C, Fink K, Huang Z, et al. Inhibition of interleukin 1b converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA 1997; 94:2007-2012.
8. Liu XH, Kwon D, Schielke GP, Yang GY, Silverstein FS, Barks JD. Mice deficient in interleukin-1 converting enzyme are resistant to neonatal hypoxic: ischemic brain damage. J Cereb Blood Flow Metab 1999; 10:1099-1108.
9. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001; 2:734-744.
10. Fogal B, Hewett SJ. Interleukin-1b: a bridge between inflammation and excitotoxicity? J Neurochem 2008; 106:1-23.
11. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992; 29:243-246.
12. Ricote M, Glass CK. PPARs and molecular mechanismsoftransrepression. Biochim Biophys Acta 2007; 1771:926-935.
13. Sakamoto J, Kimura H, Moriyama, Odaka H, Momose Y, Sugiyama Y, Sawada H. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Comm 2000; 278:704-711.
14. Victor NA, WanderiEW, Gamboa J,Zhao X, Aronowski J, Deininger K, et al. Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur J Neurosci 2006; 24:1653-1663.
15. Patzer A, Zhao Y, Stöck I, Gohlke P, Herdegen T, Culman J. Peroxisome proliferator-activated receptors g (PPARg) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. Eur J Neurosci 2008; 28:1786-1794.
16. Zhao Y, Patzer A, Gohlke P, Herdegen T, Culman J. The intracerebral application of the PPARg-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J Neurosci 2005; 22:278-282.
17. Lin TN, Cheung WM, Wu JS, Chen JJ, Lin H, Chen JJ, et al. 15d-prostaglandin J2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 2006; 26:481-487.
18. Dai WJ, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999; 30:2391-2398.
19. Garcia JH, Wagner S, Liu KF, HU XJ. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 1995; 26:627-634.
20. Zhao Y, Patzer A, Herdegen T, Gohlke P, Culman J. Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 2006; 20:1162-1175.
21. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990; 10:290-293.
22. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, Tyrrell PJ, Acute Stroke Investigators. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005; 76:1366-1372.
23. Gueorguieva I, Clark SR, McMahon CJ, Scarth S, Rothwell NJ, Tyrell PJ, et al. Pharmakokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br J Clin Pharmacol 2008; 65:317-325.
24. Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006; 34:1341-1346.
25. Yi JH, Park SW, Kapadia R, Vemuganti R. Role of transcription factors in mediating postischemic cerebral inflammation and brain damage. Neurochem Int 2007; 50:1014-1027.
26. Culman J, Zhao Y, Gohlke P, Herdegen T. PPAR-g: therapeutic target for ischemic stroke. TIPS 2007; 28:244-249.
27. Shimazu T, Inoue I, Araki N, Asano Y, Sawada M, Furuya D, et al. A peroxisome proliferator-activated receptor: gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 2005; 36:353-359.
28. Tureyen K, Kapadia R, Bowen KK, Satriatomo I, Liang J, Feinstein DL, Vemuganti R. Peroxisome proliferator-activated receptor: g agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 2007; 101:41-56.
29. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol 2005; 5:629-640.
30. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptor-g ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005; 130:685-696.
31. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-g. Nature 2005; 437:759-763.
32. Moulin D, Bianchi A, Boyault S, Sebillaud S, Koufany M, Francois M, et al. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1ß-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor b/d-dependent mechanism. Arthritis Rheum 2005; 52:759-769.
33. Pinteaux E, Trotter P, Simi A. Cell-specific and concentration-dependent actions of interleukin-1 in acute brain inflammation. Cytokine 2009; 45:1-7.
34. Mattson MP, Culmsee C, Yu ZF. Apoptotic and antiapoptotic mechanisms in stroke. Cell Tissue Res 2000; 301:173-187.